Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Seeing Clearly: A Decision Analysis of Novel MRI, PSMA PET/CT, and Biomarker Testing in Early Prostate Cancer Detection

EF 2019-20

Résumé
Prostate cancer is the most common cancer amongst men in Canada, affecting 1 in 7 individuals. MRI, PSMA PET/CT, and biomarker testing have revolutionized the approach to early stage prostate cancer detection, identifying prostate pathology in a clinically useful and reliable manner. Given the prevalence of prostate cancer, these findings are remarkably salient to early stage and undiagnosed patients. In particular, when these are used in combination, studies have reported an excellent ability to discriminate patients who do not harbour clinically significant disease from those who do. This avoids potential overtreatment in low-risk individuals while properly risk stratifying high-risk patients. Despite demonstrating clinical efficacy however, an implementation gap exists in translating these outcomes within a publicly funded, resource limited system. Rigorous Health Technology Assessment must be completed to ascertain which test(s) and in which order will offer the most benefit per cost expenditure, while addressing patient, physician, and societal acceptability concerns in Canada. To date, no decision analyses have evaluated the effect of MRI, PSMA PET/CT, and biomarker testing in a head-to-head, staged, or combination approaches within our healthcare system. Methods: We plan to evaluate the clinical and cost-effectiveness of incorporating MRI, PSMA PET/CT, and biomarker testing in primary prostate cancer detection, compared to standard of care using a decision analytic model. We will assess the detection of clinically significant prostate cancer, avoidance of clinically insignificant prostate cancer, biopsies saved, cost, and corresponding quality of life impact. Our model will determine the most clinically and cost-effective initial diagnostic strategy across a wide variety of patient, physician, and societal scenarios to inform broad-based policy decisions as well as individualized patient-level decisions.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
417002
Name
Cheung Douglas
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
Seeing Clearly: A Decision Analysis of Novel MRI, PSMA PET/CT, and Biomarker Testing in Early Prostate Cancer Detection
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Cost-Effectiveness; Decision Analysis; Detection; Diagnosis; Mri; Pet/Ct; Prostate Cancer; Psma
Abstract
Prostate cancer is the most common cancer amongst men in Canada, affecting 1 in 7 individuals. MRI, PSMA PET/CT, and biomarker testing have revolutionized the approach to early stage prostate cancer detection, identifying prostate pathology in a clinically useful and reliable manner. Given the prevalence of prostate cancer, these findings are remarkably salient to early stage and undiagnosed patients. In particular, when these are used in combination, studies have reported an excellent ability to discriminate patients who do not harbour clinically significant disease from those who do. This avoids potential overtreatment in low-risk individuals while properly risk stratifying high-risk patients. Despite demonstrating clinical efficacy however, an implementation gap exists in translating these outcomes within a publicly funded, resource limited system. Rigorous Health Technology Assessment must be completed to ascertain which test(s) and in which order will offer the most benefit per cost expenditure, while addressing patient, physician, and societal acceptability concerns in Canada. To date, no decision analyses have evaluated the effect of MRI, PSMA PET/CT, and biomarker testing in a head-to-head, staged, or combination approaches within our healthcare system. Methods: We plan to evaluate the clinical and cost-effectiveness of incorporating MRI, PSMA PET/CT, and biomarker testing in primary prostate cancer detection, compared to standard of care using a decision analytic model. We will assess the detection of clinically significant prostate cancer, avoidance of clinically insignificant prostate cancer, biopsies saved, cost, and corresponding quality of life impact. Our model will determine the most clinically and cost-effective initial diagnostic strategy across a wide variety of patient, physician, and societal scenarios to inform broad-based policy decisions as well as individualized patient-level decisions.
Competitiondate
201911
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cheung, Douglas
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~